Progress in molecularly targeted therapies for acute myeloid leukemia

Akihiro Tomita

doi:10.11406/rinketsu.56.130

Progress in molecularly targeted therapies for acute myeloid leukemia

Akihiro Tomita

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Genetic abnormalities including specific point mutations have recently been confirmed by applying comprehensive genome sequencing analyses. Molecular targeting therapies, which focus on the mutated proteins and over-expressed proteins in acute myeloid leukemia (AML) cells, are now being developed in clinical studies and/or based on in vitro analyses. This manuscript summarizes the genetic abnormalities in AML cells and some of the current molecular targeting therapies including FLT3 inhibitors (e.g. AC220; Quizartinib), Polo like kinase 1 (PLK1) inhibitors (e.g. BI-6727; Volasertib), IDH2 inhibitors (e.g. AG-221), and XPO1 inhibitors (e.g. KPT-330; Selinexor).

Original language	English
Pages (from-to)	130-138
Number of pages	9
Journal	[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume	56
Issue number	2
DOIs	https://doi.org/10.11406/rinketsu.56.130
Publication status	Published - 01-02-2015
Externally published	Yes

All Science Journal Classification (ASJC) codes

General Medicine

Access to Document

10.11406/rinketsu.56.130

Cite this

@article{21b513b795c64aa9a3f5b0aa8ff04996,

title = "Progress in molecularly targeted therapies for acute myeloid leukemia",

abstract = "Genetic abnormalities including specific point mutations have recently been confirmed by applying comprehensive genome sequencing analyses. Molecular targeting therapies, which focus on the mutated proteins and over-expressed proteins in acute myeloid leukemia (AML) cells, are now being developed in clinical studies and/or based on in vitro analyses. This manuscript summarizes the genetic abnormalities in AML cells and some of the current molecular targeting therapies including FLT3 inhibitors (e.g. AC220; Quizartinib), Polo like kinase 1 (PLK1) inhibitors (e.g. BI-6727; Volasertib), IDH2 inhibitors (e.g. AG-221), and XPO1 inhibitors (e.g. KPT-330; Selinexor). ",

author = "Akihiro Tomita",

year = "2015",

month = feb,

day = "1",

doi = "10.11406/rinketsu.56.130",

language = "English",

volume = "56",

pages = "130--138",

journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",

issn = "0485-1439",

publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",

number = "2",

}

TY - JOUR

T1 - Progress in molecularly targeted therapies for acute myeloid leukemia

AU - Tomita, Akihiro

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Genetic abnormalities including specific point mutations have recently been confirmed by applying comprehensive genome sequencing analyses. Molecular targeting therapies, which focus on the mutated proteins and over-expressed proteins in acute myeloid leukemia (AML) cells, are now being developed in clinical studies and/or based on in vitro analyses. This manuscript summarizes the genetic abnormalities in AML cells and some of the current molecular targeting therapies including FLT3 inhibitors (e.g. AC220; Quizartinib), Polo like kinase 1 (PLK1) inhibitors (e.g. BI-6727; Volasertib), IDH2 inhibitors (e.g. AG-221), and XPO1 inhibitors (e.g. KPT-330; Selinexor).

AB - Genetic abnormalities including specific point mutations have recently been confirmed by applying comprehensive genome sequencing analyses. Molecular targeting therapies, which focus on the mutated proteins and over-expressed proteins in acute myeloid leukemia (AML) cells, are now being developed in clinical studies and/or based on in vitro analyses. This manuscript summarizes the genetic abnormalities in AML cells and some of the current molecular targeting therapies including FLT3 inhibitors (e.g. AC220; Quizartinib), Polo like kinase 1 (PLK1) inhibitors (e.g. BI-6727; Volasertib), IDH2 inhibitors (e.g. AG-221), and XPO1 inhibitors (e.g. KPT-330; Selinexor).

UR - https://www.scopus.com/pages/publications/84942508664

UR - https://www.scopus.com/inward/citedby.url?scp=84942508664&partnerID=8YFLogxK

U2 - 10.11406/rinketsu.56.130

DO - 10.11406/rinketsu.56.130

M3 - Article

C2 - 25765792

AN - SCOPUS:84942508664

SN - 0485-1439

VL - 56

SP - 130

EP - 138

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

IS - 2

ER -

Progress in molecularly targeted therapies for acute myeloid leukemia

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this